Search

everythinglearnresearchcommunity

for

Search:↓

Adipose stem cell exosomes can effectively reduce facial redness and improve skin health in atopic dermatitis patients.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.

Exosomes show promise as effective treatments for autoimmune skin diseases with fewer side effects.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Enteral nutrition's role in maintaining Crohn's disease remission is unclear and needs more research.

Ritlecitinib can help about 14,000 people with severe hair loss.

Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Ritlecitinib works well and is safe for treating alopecia areata.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

The rash resolved after stopping ponatinib.